Medical devices, healthcare technology and the business of care
PMA approval · P000015

NUCLEUS 24 AUDITORY BRAINSTEM IMPLANT SYSTEM

Cochlear Americas · Decision date Oct 20, 2000

MEDTECHLEDGER EXPLANATIONP000015

What did the FDA approve?

The FDA approved the Nucleus 24 Auditory Brainstem Implant System for individuals 12 years or older diagnosed with neurofibromatosis type 2. The device is intended to restore useful hearing through electrical stimulation of the cochlear nucleus. Implantation may occur during first or second-side tumor removal, or in patients with previously removed acoustic tumors bilaterally.

The approval statement notes that the surgical procedure for tumor excision and electrode placement eliminates residual hearing, so preoperative audiological criteria are not relevant. Prospective recipients and their families should have appropriate expectations regarding potential benefits and should be motivated to participate in postoperative rehabilitation. The statement reports the device's intended purpose but does not independently establish safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE NUCLEUS 24 AUDITORY BRAINSTEM IMPLANT (ABI) SYSTEM, WHICH IS INTENDED TO RESTORE USEFUL HEARING VIA ELECTRICAL STIMULATION OF THE COCHLEAR NUCLEUS. THE DEVICE IS INDICATED FOR INDIVIDUALS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN DIAGNOSED WITH NEUROFIBROMATOSIS TYPE 2 (NF2). IMPLANTATION MAY OCCUR DURING FIRST OR SECOND-SIDE TUMOR REMOVAL, OR IN PATIENTS WITH PREVIOUSLY REMOVED ACOUSTIC TUMORS BILATERALLY. BECAUSE THE SURGICAL PROCEDURE FOR TUMOR EXCISION AND ELECTRODE PLACEMENT ELIMINATES RESIDUAL HEARING, PREOPERATIVE AUDIOLOGICAL CRITERIA ARE NOT RELEVANT. PROSPECTIVE IMPLANT RECIPIENTS AND THEIR FAMILIES SHOULD HAVE APPROPRIATE EXPECTATIONS, REGARDING THE POTENTIAL BENEFITS OF AN AUDITORY BRAINSTEM IMPLANT AND SHOULD BE HIGHLY MOTIVATED TO PARTICIPATE IN THE POSTOPEARATIVE REHABILITATION PROCESS.
Regulatory pathway
Original PMA
Clinical specialty
Ear, Nose, Throat
Decision date
Oct 20, 2000

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P000015
Regulatory pathway
Premarket approval application
Product code
MHE
Decision code
APPR
Decision date
Oct 20, 2000
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, auditory brainstem.

Product code
MHE
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P000015 received

    Application receipt date recorded by FDA.

  2. P000015 · FDA decision

    APPR

  3. P000015/S057 · Related supplement

    Cochlear Auditory Brainstem Implant System

Timeline entries are records held by MedtechLedger for P000015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000015

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA supplementSep 28, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cochlear Americas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10350 Park Meadows Dr., Lone Tree, CO, 80124

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records